Lessons for Biopharma From the Battle of Entresto®

After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp. (“Novartis”)’s Entresto® have entered the market….
By: Fish & Richardson